Lyell Immunopharma (NASDAQ:LYEL) Stock Bumped Up to "Hold" by Wall Street Zen

Key Points

• Wall Street Zen upgraded Lyell Immunopharma from “Sell” to “Hold,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $40.86.
• Lyell shares opened at $9.39, well below the $40.86 consensus target, with a market capitalization of approximately $230 million and a one-year range of $7.20 to $45.00.
• The clinical-stage biotechnology company remains unprofitable, reporting a quarterly loss of $1.92 per share and forecasting a full-year loss of $7.16 per share; institutional investors own about 66.05% of its stock.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday, Wall Street Zen reports.

A number of other research analysts have also weighed in on LYEL. Needham & Company LLC reissued a "buy" rating and set a $44.00 price target on shares of Lyell Immunopharma in a research report on Friday, September 11th. HC Wainwright reaffirmed a "buy" rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. B. Riley Financial initiated coverage on shares of Lyell Immunopharma in a research note on Wednesday, July 22nd. They issued a "buy" rating and a $44.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Lyell Immunopharma in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada set a $34.00 target price on shares of Lyell Immunopharma in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Lyell Immunopharma currently has an average rating of "Moderate Buy" and a consensus target price of $40.86.

Lyell Immunopharma Trading Up 0.1%

Lyell Immunopharma stock opened at $9.39 on Friday. The firm has a market capitalization of $230.09 million, a price-to-earnings ratio of -0.73 and a beta of -0.03. The firm's fifty day moving average price is $11.47 and its two-hundred day moving average price is $14.67. Lyell Immunopharma has a 1-year low of $7.20 and a 1-year high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, topping the consensus estimate of ($1.94) by $0.02. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. On average, research analysts forecast that Lyell Immunopharma will post -7.16 EPS for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of hedge funds have recently made changes to their positions in the business. venBio Partners LLC purchased a new stake in Lyell Immunopharma during the second quarter valued at about $4,744,643. Opaleye Management Inc. increased its stake in shares of Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company's stock worth $4,834,000 after purchasing an additional 264,928 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company's stock valued at $2,335,000 after buying an additional 76,921 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Lyell Immunopharma during the 1st quarter valued at approximately $959,000. Finally, Bank of America Corp DE lifted its stake in shares of Lyell Immunopharma by 314.2% during the 1st quarter. Bank of America Corp DE now owns 33,321 shares of the company's stock valued at $668,000 after buying an additional 25,276 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell's research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.